Cargando…
Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
Molecular imaging of the immune checkpoint receptor PD-1 and its ligand PD-L1 is increasingly investigated as a strategy to guide and monitor PD-1:PD-L1-targeted immune checkpoint therapy. We provide an overview of the current state-of-the-art on PD-1- and PD-L1-specific imaging agents for quantitat...
Autores principales: | Broos, Katrijn, Lecocq, Quentin, Raes, Geert, Devoogdt, Nick, Keyaerts, Marleen, Breckpot, Karine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037030/ https://www.ncbi.nlm.nih.gov/pubmed/30026866 http://dx.doi.org/10.7150/thno.24762 |
Ejemplares similares
-
Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers
por: Broos, Katrijn, et al.
Publicado: (2017) -
Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent
por: Broos, Katrijn, et al.
Publicado: (2019) -
Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation
por: Bridoux, Jessica, et al.
Publicado: (2020) -
Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade
por: Awad, Robin Maximilian, et al.
Publicado: (2021) -
Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production
por: Broos, Katrijn, et al.
Publicado: (2019)